Cough in idiopathic pulmonary fibrosis

European Respiratory Review

Volumn 25, Issue 141, 2016, Pages 278-286

  Van Manen, Mirjam J G ^a   Birring, Surinder S ^b   Vancheri, Carlo ^c   Cottin, Vincent ^d   Renzoni, Elisabetta A ^e   Russell, Anne Marie ^e,f   Wijsenbeek, Marlies S ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF CATANIA   (Italy)

^d UNIVERSITÉ LYON 1   (France)

^e ROYAL BROMPTON HOSPITAL   (United Kingdom)

^f NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NEUROTROPIN; PREDNISONE; THALIDOMIDE; TRANSIENT RECEPTOR POTENTIAL CHANNEL A1; VANILLOID RECEPTOR 1; ANTITUSSIVE AGENT;

BRONCHUS MUCOSA; CHRONIC COUGH; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; COMORBIDITY; COUGHING; DISEASE COURSE; DIZZINESS; EPITHELIUM CELL; FIBROSING ALVEOLITIS; GASTROESOPHAGEAL REFLUX; HUMAN; LYMPHOCYTE; MACROPHAGE; MESENCHYME CELL; NEUROPATHY; PATHOPHYSIOLOGY; POSITIVE END EXPIRATORY PRESSURE; PREVALENCE; PROTEIN EXPRESSION; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SLEEP DISORDERED BREATHING; SURVIVAL RATE; ANIMAL; CHRONIC DISEASE; COMPLICATION; COUGH; IDIOPATHIC PULMONARY FIBROSIS; PROGNOSIS;

ANIMALS; ANTITUSSIVE AGENTS; CHRONIC DISEASE; COMORBIDITY; COUGH; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; PROGNOSIS; QUALITY OF LIFE; RISK FACTORS;

EID: 84986238365     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/16000617.0090-2015     Document Type: Review

References (69)

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
2. Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA). The Voice of the Patient: A series of reports from the U.S. Food and Drug Administration’s (FDA’s) Patient-Focused Drug Development Initiative. www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM440829.pdf Date last updated: March, 2015.
3. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083-2092.
4. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071-2082.
5. Ryerson CJ, Abbritti M, Ley B, et al. Cough predicts prognosis in idiopathic pulmonary fibrosis. Respirology 2011; 16: 969-975.
6. Chung KF, Pavord ID. Prevalence, pathogenesis, and causes of chronic cough. Lancet 2008; 371: 1364-1374.
7. Morice AH. Epidemiology of cough. Pulm Pharmacol Ther 2002; 15: 253-259.
8. Hope-Gill BDM, Hilldrup S, Davies C, et al. A study of the cough reflex in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168: 995-1002.
9. Swigris JJ, Stewart AL, Gould MK, et al. Patients’ perspectives on how idiopathic pulmonary fibrosis affects the quality of their lives. Health Qual Life Outcomes 2005; 3: 61.
10. Key AL, Holt K, Hamilton A, et al. Objective cough frequency in idiopathic pulmonary fibrosis. Cough 2010; 6: 4.
11. Van Manen M, Birring S, Vancheri C, et al. Cough measurements in patients with idiopathic pulmonary fibrosis (IPF). Am J Respir Crit Care Med 2015; 191: A4422.
12. Sumner H, Woodcock A, Kolsum U, et al. Predictors of objective cough frequency in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187: 943-949.
13. Dicpinigaitis PV. Cough reflex sensitivity in cigarette smokers. Chest 2003; 123: 685-688.
14. Morice AH, Fontana GA, Belvisi MG, et al. ERS guidelines on the assessment of cough. Eur Respir J 2007; 29: 1256-1276.
15. Birring SS, Prudon B, Carr AJ, et al. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax 2003; 58: 339-343.
16. Bradaia F, Lazor R, Khouatra C, et al. Incontinence urinaire a la toux au cours des pneumopathies interstitielles diffuses [Urinary incontinence due to chronic cough in interstitial lung disease]. Rev Mal Respir 2009; 26: 499-504.
17. Lee K, Birring S. Cough. Medicine 2012; 40: 173-176.
18. Pacheco A. Chronic cough: from a complex dysfunction of the neurological circuit to the production of persistent cough. Thorax 2014; 69: 881-883.
19. Morice AH, Millqvist E, Belvisi MG, et al. Expert opinion on the cough hypersensitivity syndrome in respiratory medicine. Eur Respir J 2014; 44: 1132-1148.
20. Polverino M, Polverino F, Fasolino M, et al. Anatomy and neuro-pathophysiology of the cough reflex arc. Multidiscip Respir Med 2012; 7: 5.
21. Banner KH, Igney F, Poll C. TRP channels: emerging targets for respiratory disease. Pharmacol Ther 2011; 130: 371-384.
22. Jones RM, Hilldrup S, Hope-Gill BD, et al. Mechanical induction of cough in idiopathic pulmonary fibrosis. Cough 2011; 7: 2.
23. Harrison NK, Pynn MC. Nerves, cough, and idiopathic pulmonary fibrosis. EMJ Respir 2015; 3: 38-45.
24. Lieu TM, Myers AC, Meeker S, et al. TRPV1 induction in airway vagal low-threshold mechanosensory neurons by allergen challenge and neurotrophic factors. Am J Physiol Lung Cell Mol Physiol 2012; 302: L941-L948.
25. Harrison NK. Idiopathic pulmonary fibrosis: a nervous cough? Pulm Pharmacol Ther 2004; 17: 347-350.
26. Doherty MJ, Mister R, Pearson MG, et al. Capsaicin induced cough in cryptogenic fibrosing alveolitis. Thorax 2000; 55: 1028-1032.
27. Harrison NK. Cough, sarcoidosis and idiopathic pulmonary fibrosis: raw nerves and bad vibrations. Cough 2013; 9: 9.
28. Ricci A, Felici L, Mariotta S, et al. Neurotrophin and neurotrophin receptor protein expression in the human lung. Am J Respir Cell Mol Biol 2004; 30: 12-19.
29. Ricci A, Graziano P, Bronzetti E, et al. Increased pulmonary neurotrophin protein expression in idiopathic interstitial pneumonias. Sarcoidosis Vasc Diffuse Lung Dis 2007; 24: 13-23.
30. Olgart Höglund C, de Blay F, Oster JP, et al. Nerve growth factor levels and localisation in human asthmatic bronchi. Eur Respir J 2002; 20: 1110-1116.
31. Leslie KO. Idiopathic pulmonary fibrosis may be a disease of recurrent, tractional injury to the periphery of the aging lung: a unifying hypothesis regarding etiology and pathogenesis. Arch Pathol Lab Med 2012; 136: 591-600.
32. Ghatol A, Ruhl AP, Danoff SK. Exacerbations in idiopathic pulmonary fibrosis triggered by pulmonary and nonpulmonary surgery: a case series and comprehensive review of the literature. Lung 2012; 190: 373-380.
33. Mazzone SB, McLennan L, McGovern AE, et al. Representation of capsaicin-evoked urge-to-cough in the human brain using functional magnetic resonance imaging. Am J Respir Crit Care Med 2007; 176: 327-332.
34. Leech J, Mazzone SB, Farrell MJ. Brain activity associated with placebo suppression of the urge-to-cough in humans. Am J Respir Crit Care Med 2013; 188: 1069-1075.
35. Madison JM, Irwin RS. Chronic cough in adults with interstitial lung disease. Curr Opin Pulm Med 2005; 11: 412-416.
36. Lamas DJ, Kawut SM, Bagiella E, et al. Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study. Am J Respir Crit Care Med 2011; 184: 842-847.
37. Tobin RW, Pope CE 2nd, Pellegrini CA, et al. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 158: 1804-1808.
38. Pillai M, Olson AL, Huie TJ, et al. Obstructive sleep apnea does not promote esophageal reflux in fibrosing interstitial lung disease. Respir Med 2012; 106: 1033-1039.
39. Mermigkis C, Stagaki E, Tryfon S, et al. How common is sleep-disordered breathing in patients with idiopathic pulmonary fibrosis? Sleep Breath 2010; 14: 387-390.
40. Lancaster LH, Mason WR, Parnell JA, et al. Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. Chest 2009; 136: 772-778.
41. Fell CD. Idiopathic pulmonary fibrosis: phenotypes and comorbidities. Clin Chest Med 2012; 33: 51-57.
42. Scholand MB, Wolff R, Crossno PF, et al. Severity of cough in idiopathic pulmonary fibrosis is associated with MUC5 B genotype. Cough 2014; 10: 3.
43. Horton MR, Santopietro V, Mathew L, et al. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. Ann Intern Med 2012; 157: 398-406.
44. Kreuter M, Ehlers-Tenenbaum S, Schaaf M, et al. Treatment and outcome of lung cancer in idiopathic interstitial pneumonias. Sarcoidosis Vasc Diffuse Lung Dis 2015; 31: 266-274.
45. Perng DW, Chang KT, Su KC, et al. Exposure of airway epithelium to bile acids associated with gastroesophageal reflux symptoms: a relation to transforming growth factor-beta1 production and fibroblast proliferation. Chest 2007; 132: 1548-1556.
46. Lee JS, Collard HR, Raghu G, et al. Does chronic microaspiration cause idiopathic pulmonary fibrosis? Am J Med 2010; 123: 304-311.
47. Ing AJ, Ngu MC, Breslin AB. Pathogenesis of chronic persistent cough associated with gastroesophageal reflux. Am J Respir Crit Care Med 1994; 149: 160-167.
48. Kilduff CE, Counter MJ, Thomas GA, et al. Effect of acid suppression therapy on gastroesophageal reflux and cough in idiopathic pulmonary fibrosis: an intervention study. Cough 2014; 10: 4.
49. Mermigkis C, Bouloukaki I, Antoniou K, et al. Obstructive sleep apnea should be treated in patients with idiopathic pulmonary fibrosis. Sleep Breath 2015; 19: 385-391.
50. Birring SS, Ing AJ, Chan K, et al. Obstructive sleep apnoea: a cause of chronic cough. Cough 2007; 3: 7.
51. Jung HK, Choung RS, Talley NJ. Gastroesophageal reflux disease and sleep disorders: evidence for a causal link and therapeutic implications. J Neurogastroenterol Motil 2010; 16: 22-29.
52. Chan KK, Ing AJ, Laks L, et al. Chronic cough in patients with sleep-disordered breathing. Eur Respir J 2010; 35: 368-372.
53. Eskiizmir G, Kezirian E. Is there a vicious cycle between obstructive sleep apnea and laryngopharyngeal reflux disease? Med Hypotheses 2009; 73: 706-708.
54. Chan K, Ing A, Birring SS. Cough in obstructive sleep apnoea. Pulm Pharmacol Ther 2015; 35: 129-131.
55. Boulet LP, Coeytaux RR, McCrory DC, et al. Tools for assessing outcomes in studies of chronic cough: CHEST guideline and expert panel report. Chest 2015; 147: 804-814.
56. Lee KK, Matos S, Evans DH, et al. A longitudinal assessment of acute cough. Am J Respir Crit Care Med 2013; 187: 991-997.
57. Lechtzin N, Hilliard ME, Horton MR. Validation of the cough quality-of-life questionnaire in patients with idiopathic pulmonary fibrosis. Chest 2013; 143: 1745-1749.
58. Morice AH, Kastelik JA, Thompson R. Cough challenge in the assessment of cough reflex. Br J Clin Pharmacol 2001; 52: 365-375.
59. Spinou A, Birring SS. An update on measurement and monitoring of cough: what are the important study endpoints? J Thorac Dis 2014; 6: Suppl. 7, S728-S734.
60. Birring SS, Spinou A. How best to measure cough clinically. Curr Opin Pharmacol 2015; 22: 37-40.
61. Lee JS, Collard HR, Anstrom KJ, et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med 2013; 1: 369-376.
62. Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 2015; 192: e3-e19.
63. Azuma A, Taguchi Y, Ogura T, et al. Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. Respir Res 2011; 12: 143.
64. Wijsenbeek MS, Van Beek FT, Geel AL, et al. Pirfenidone in daily clinical use in patients with idiopathic pulmonary fibrosis in the Netherlands. Am J Respir Crit Care Med 2013; 187: A4340.
65. Okazaki A, Ohkura N, Fujimura M, et al. Effects of pirfenidone on increased cough reflex sensitivity in guinea pigs. Pulm Pharmacol Ther 2013; 26: 603-608.
66. Vertigan AE, Kapela SL, Ryan NM, et al. Pregabalin and speech pathology combination therapy for refractory chronic cough: a randomised controlled trial. Chest 2016; 149: 639-648.
67. Ryan NM, Birring SS, Gibson PG. Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. Lancet 2012; 380: 1583-1589.
68. Patel AS, Watkin G, Willig B, et al. Improvement in health status following cough-suppression physiotherapy for patients with chronic cough. Chron Respir Dis 2011; 8: 253-258.
69. Abdulqawi R, Dockry R, Holt K, et al. P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 2015; 385: 1198-1205.